probability-based sample of the U.S. population. We propose the following data collection instruments:

(1) *Parent Survey:* We will administer this as a web survey. Information collected through the Parent Survey will be used to report on demographics, the parent-child relationship, parents' attitudes and beliefs about youth sex education and sexual behaviors, and parental knowledge about youth sexual risk-taking.

(2) *Youth Survey:* We will administer a web survey in two parts to youth ages 14–18. Information collected on Part I of the survey will be used to report on demographics, the parent-child relationship, future aspirations, and attitudes and beliefs about youth sexual behavior. Information collected on Part II of the survey will include knowledge about sexual risk, experience with sex education, and sexual risk behaviors.

(3) *Young Adult Survey:* We will administer this to young adults ages 19–24 as a web survey. Topics align with the youth survey, but with slight wording changes to reflect the older population.

Respondents: The survey respondents are from an online panel of a probability-based sample of the U.S. population of parents of youth ages 14–18 and their youth ages 14–18 and of young adults ages 19–24.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents (total over request period)	Number of responses per respondent (total over request period)	Average burden per response (in hours)	Total burden (in hours)	Annual burden (in hours)
(1) Parent Survey	1,550	1	.333	516	172
(2) Part I Youth Survey	675	1	.333	225	75
(3) Part II Youth Survey	540	1	.333	180	60
(4) Young Adult Survey	775	1	.583	452	151

Estimated Total Annual Burden Hours: 458.

Comments: The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

(Authority: **SEC**. 510. [42 U.S.C. 710])

Mary B. Jones,

ACF/OPRE Certifying Officer.

[FR Doc. 2020–06867 Filed 4–1–20; 8:45 am]

BILLING CODE 4184–83–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; State Plan Child Support Collection and Establishment of Paternity Title IV–D OCSE–100 and OCSE–21–U4

AGENCY: Office of Child Support Enforcement, Administration for Children and Families, HHS.

ACTION: Request for public comment.

SUMMARY: The Office of Child Support Enforcement (OCSE), Administration for Children and Families (ACF), U.S. Department of Health and Human Services (HHS), is requesting a three-year extension of the forms OCSE–21–U4: Transmittal and Notice of Approval of State Plan Material for: Title IV–D of the Social Security Act and OCSE–100: State Plan (OMB #0970–0017, expiration 7/31/2020).

DATES: *Comments due within 30 days of publication.* OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, Email: *OIRA_SUBMISSION@OMB.EOP.GOV,* Attn: Desk Officer for the Administration for Children and Families.

Copies of the proposed collection may be obtained by emailing *infocollection@acf.hhs.gov.* Alternatively, copies can also be obtained by writing to the Administration for Children and Families, Office of Planning, Research, and Evaluation, 330 C Street SW, Washington, DC 20201, Attn: ACF Reports Clearance Officer. All requests, emailed or written, should be identified by the title of the information collection.

SUPPLEMENTARY INFORMATION:

Description: OCSE has approved an IV–D state plan for each state. Federal regulations require states to amend their state plans only when necessary to reflect new or revised federal statutes, regulations, or material changes in any state laws, regulations, policies, or IV–D agency procedures. The requirement for submission of a state plan and plan amendments for the Child Support Enforcement Program is found in sections 452, 454, and 466 of the Social Security Act. OCSE made minor revisions to the OCSE–21–U4 to remove outdated language and add an option for states to electronically request or renew an exemption from the mandatory laws and procedures in Section 466 of the Social Security Act via the online state plan system. These revisions do not increase the burden of the OCSE–21–U4.

Respondents: State IV–D Agencies.

ANNUAL BURDEN ESTIMATES

Instrument	Total number of respondents	Total number of responses per respondent	Average burden hours per response	Total burden hours
State Plan (OCSE–100)	54	12	.5	324
State Plan Transmittal (OCSE–21–U4)	54	12	.25	162

Estimated Total Annual Burden Hours: 486.

(Authority: Sections 452, 454, and 466 of the Social Security Act)

Mary B. Jones,

ACF/OPRE Certifying Officer.

[FR Doc. 2020–06869 Filed 4–1–20; 8:45 am]

BILLING CODE 4184–41–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Advancing Translational Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Advancing Translational Sciences Special Emphasis Panel CTSA.

Date: May 8, 2020.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate cooperative agreement applications.

Place: National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual and Teleconference Meeting).

Contact Person: Victor Henriquez, Ph.D., Scientific Review Officer, Office of Scientific Director, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, 6701 Democracy Blvd., Democracy 1, Room 1080, Bethesda, MD 20892–4878, 301–435–0813 *henriquv@mail.nih.gov,*

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: March 27, 2020.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020–06870 Filed 4–1–20; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of an Exclusive Patent License: Methods and Compositions for Adoptive Cell Therapy

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Lyell Immunopharma, Inc. (''Lyell''), located in South San Francisco, CA.

DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before April 17, 2020 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Andrew Burke, Ph.D., Senior Technology Transfer Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530, MSC 9702, Bethesda, MD 20892–9702 (for business mail), Rockville, MD 20850–9702; Telephone: (240) 276–5484; Facsimile: (240) 276–5504; Email: *andy.burke@nih.gov.*

SUPPLEMENTARY INFORMATION:

Intellectual Property

Group A

E–022–2017: Methods for Selecting Therapy for a Cancer Patient

1. US Provisional Patent Application 62/418,461 filed November 7, 2016 (E–022–2017–0–US–01);

2. International Patent Application PCT/US2017/060304 filed November 7, 2017 (E–022–2017–0–PCT–02);

3. European Patent Application 17805342.7 filed May 6, 2019 (E–022–2017–0–EP–03); and

4. United States Patent Application 16/347,778 filed May 6, 2019 (E–022–2017–0–US–04).

Group B

E–250–2016: Methods of Preparing an Isolated or Purified Population of Thymic Emigrant Cells and Methods of Treatment Using the Same

1. US Provisional Patent Application 62/433,591 filed December 13, 2016 (E–250–2016–0–US–01);

2. International Patent Application PCT/US2017/065986 filed December 13, 2017 (E–250–2016–0–PCT–02);

3. European Patent Application 17825696.2 filed June 11, 2019 (E–250–2016–0–EP–03); and

4. United States Patent Application 16/468,890 filed June 12, 2019 (E–250–2016–0–US–04).

E–132–2017: Methods of Preparing Hematopoietic Progenitor Cells In Vitro

1. US Provisional Patent Application 62/583,240 filed November 8, 2017 (E–132–2017–0–US–01); and

2. International Patent Application PCT/US2018/059856 filed November 8, 2018 (E–132–2017–0–PCT–02).

E–133–2017: In Vitro Generation of Thymic Organoid From Human Pluripotent Stem Cells

1. US Provisional Patent Application 62/560,908 filed September 20, 2017 (E–133–2017–0–US–01); and

2. International Patent Application PCT/US2018/051625 filed September 19, 2018 (E–133–2017–0–PCT–02).